Weekly Top News – Psoriasis – November 4, 2019

November 4, 2019

Cosentyx (secukinumab) / Novartis; Humira (adalimumab) / Eisai, AbbVie
Novartis Cosentyx shows encouraging results versus Humira from first of its kind head-to-head trial in psoriatic arthritis (Novartis Press Release) – Nov 1, 2019 – P3, N=850; EXCEED (NCT02745080); Sponsor: Novartis Pharmaceuticals; “Novartis…announced results from the EXCEED head-to-head trial comparing Cosentyx® (secukinumab) to Humira…in patients with active psoriatic arthritis (PsA)[1]. While Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, it showed numerically higher results versus Humira…Statistically significant advantages of Cosentyx versus Humira®* in PsA-specific endpoints were observed in a pre-specified sensitivity analysis. The trial demonstrated a consistent and favorable safety profile for Cosentyx in line with previous clinical trials…No new safety signals were detected.”


Taltz (ixekizumab) / Eli Lilly
Lilly presents positive results for Taltz (ixekizumab) in pediatric patients with moderate to severe plaque psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress (GlobeNewswire) – Oct 28, 2019 – P3, N=201; “Eli Lilly and Company announced that TALTZ met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe plaque psoriasis…Results of the study were presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress (EADV) in Madrid, Spain. Based on these positive results, Lilly plans to submit for U.S. regulatory approval for pediatric patients with moderate to severe plaque psoriasis.”


Humira (adalimumab) / Eisai, AbbVie; Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
AbbVie to showcase depth of immunology portfolio and pipeline at the 2019 ACR/ARP Annual Meeting (PRNewswire) – Nov 4, 2019 – “AbbVie…today announced it will present data from multiple studies of RINVOQ™ (upadacitinib), HUMIRA® (adalimumab) and SKYRIZI™ (risankizumab) at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting, November 8-13, in Atlanta. A total of 38 abstracts will be presented across multiple rheumatic conditions, including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA).”


Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
AbbVie’s new psoriasis drug likely to win nod this year (Korea Biomedical Review) – Oct 30, 2019 – “AbbVie’s new psoriasis treatment Risankizumab is likely to obtain local license within this year, heating the competition in the psoriasis treatment market….The Ministry of Food and Drug Safety is reviewing the drug for approval, sources said.”


Stelara (ustekinumab) / J&J; Remicade (infliximab) / Mitsubishi Tanabe, J&J; Tremfya (guselkumab) / J&J; Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Janssen presenting data from its expanding rheumatology portfolio at the 2019 annual meeting of The American College of Rheumatology (PRNewswire) – Oct 31, 2019 – “The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will be presenting results from 30 abstracts across the company’s expanding rheumatology portfolio and pipeline products during the 2019 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) Annual Meeting taking place in Atlanta, Georgia from November 8-13.”


Stelara (ustekinumab) / J&J
Stelara patent expiry: July 2024 in EU (Kepler Cheuvreux) – Oct 31, 2019 – A subscription to Thomson ONE is required to gain full access to report 68195721; Page no: 1; REPORT TITLE: “Formycon AG Espresso Note | Formycon | Buy | start of phase I for FYB202”; AUTHOR: Choplain, Damien, et al; DATE: 10/28/2019


Siliq (brodalumab) / Bausch Health, Leo Pharma, Kyowa Hakko Kirin
Ahead of World Psoriasis Day, Bausch Health, Canada announces that Siliq (brodalumab) is now covered on most drug benefit formularies in Canada (Yahoo Finance) – Oct 29, 2019 – “In advance of World Psoriasis Day on October 29, 2019 , Bausch Health Companies…is pleased to announce that SILIQ (brodalumab)3 is now listed on the majority of provincial drug benefit formularies in Canada , ensuring improved treatment access for the nearly 800,000 Canadians currently living with plaque psoriasis.”


Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Skyrizi US sales projection: $142M in Q4 2019 and $268M in FY2019 (UBS) – Oct 29, 2019 – A subscription to Thomson ONE is required to gain full access to report 68132444; Page no: 1; REPORT TITLE: “US Pharmaceuticals “Drug launches – weekly tracker” Jacob”; AUTHOR: Jacob, Navin, et al; DATE: 10/18/2019

No Comments

Post a Comment